.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Prof. Dr. Reinhard Henschler

Leipzig/ DE

University Hospital Leipzig

Chair

22/09/2023
13:30 – 14:30
Abstractsitzungen
Immunotherapy 2 - Engineered Cells
MOA 04+05

Further involvements

20/09/2023
12:30 – 12:45 12 Min. 3 Min.
Freier Vortrag
VS-5-3
Characterization of stem cell product quality in vitro and by in vivo function through hematopoietic engraftment
Allogeneic regenerative Cell Therapy
20/09/2023
12:45 – 13:00 12 Min. 3 Min.
Freier Vortrag
VS-4-5
Selection of exchange fluid for therapeutic plasma exchange (Leipzig Protocol)
Hemotherapy
20/09/2023
15:30 – 15:45 12 Min. 3 Min.
Freier Vortrag
VS-9-3
Demographic behaviour of whole blood donors in a regional blood service - Implications for donor recruitment policies
Blood Donation
20/09/2023
15:45 – 16:00 12 Min. 3 Min.
Freier Vortrag
VS-9-4
Pretransfusional electronic crossmatch prevents transfusion to the wrong patient
Hemotherapy
21/09/2023
16:51 – 16:54 2 Min. 1 Min.
ePoster
PS-2-8
Production of metabolically improved Red Cell Concentrates under an new GMP Protocol under Hypoxia
Blood Components